.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
McKesson
Merck
AstraZeneca
Queensland Health
Argus Health
Fuji
Federal Trade Commission
US Army

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,271,941

« Back to Dashboard

Which drugs does patent 9,271,941 protect, and when does it expire?


Patent 9,271,941 protects MEKINIST and is included in one NDA.

This patent has twenty-seven patent family members in twenty-three countries.

Summary for Patent: 9,271,941

Title:Pharmaceutical composition
Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-tr- ioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.
Inventor(s): DeMarini; Douglas J. (Collegeville, PA), Henriquez; Francisco (Collegeville, PA), Le; Ngocdiep T. (Collegeville, PA), Wang; Lihong (Collegeville, PA)
Assignee: Novartis AG (Basel, CH)
Application Number:14/044,139
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-002May 29, 2013DISCNYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-003May 29, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,271,941

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,304Pharmaceutical composition► Subscribe
9,399,021Pharmaceutical composition► Subscribe
9,155,706Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,271,941

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Costa Rica20130352► Subscribe
Dominican RepublicP2013000138► Subscribe
Eurasian Patent Organization201390913► Subscribe
Eurasian Patent Organization025198► Subscribe
European Patent Office2654736► Subscribe
Israel226855► Subscribe
Japan2014510704► Subscribe
Japan6126014► Subscribe
Japan2017137299► Subscribe
South Korea20130130028► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Federal Trade Commission
McKesson
Colorcon
Daiichi Sankyo
Teva
QuintilesIMS
Express Scripts
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot